ZYVERSA THERAPEUTICS INC (ZVSA) Stock News

NASDAQ:ZVSA - US98987D3008 - Common Stock

0.3113 USD

-0.24 (-43.3%)

Last: 7/16/2025, 8:00:02 PM

0.289 USD

-0.02 (-7.16%)

After Hours: 7/16/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ZVSA Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

20 days ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

21 days ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

21 days ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

a month ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

a month ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

2 months ago - By: Benzinga - Mentions: CYCC SSII ONCO CUE ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

2 months ago - By: Benzinga - Mentions: EVOK RYTM BSGM WINT ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

2 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

4 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

4 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

4 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

4 months ago - By: ZyVersa Therapeutics

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

4 months ago - By: ZyVersa Therapeutics

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

4 months ago - By: ZyVersa Therapeutics

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update